Reuters logo
BRIEF-Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy
May 10, 2017 / 8:21 PM / 5 months ago

BRIEF-Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy

May 10 (Reuters) - Pfizer Inc

* Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy

* Sangamo Therapeutics Inc says under terms of collaboration agreement, Sangamo will receive a $70 million upfront payment from Pfizer

* Sangamo Therapeutics Inc says Sangamo will be responsible for conducting SB-525 phase 1/2 clinical study and certain manufacturing activities

* Sangamo -Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525

* Sangamo Therapeutics Inc says Sangamo is eligible to receive potential milestone payments of up to $475 million

* Sangamo Therapeutics Inc says Sangamo will also receive tiered double-digit royalties on net sales

* Sangamo Therapeutics Inc says additionally, Sangamo will be collaborating with Pfizer on manufacturing and technical operations utilizing viral delivery vectors Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below